Assembly Biosciences (ASMB) Stock Price, Quote & News

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 509 4583

Website: www.assemblybio.com

Address:

Two Tower Place, 7th Floor, South San Francisco, United States

havivi77 Oct. 24 at 8:31 PM

$ASMB accumulation is still on going… explosion has not happened yet…

0 · Reply

Dachshundtrader Oct. 24 at 5:08 PM

$ASMB up ~8% on almost no volume today. Not hype, not noise — just what happens when a tiny float meets a bit of quiet accumulation. Sometimes the calmest days say the most. $GILD

0 · Reply

Jkwran69 Oct. 21 at 7:49 PM

$ASMB did something negative happen at their investment conference today?

1 · Reply

CantNameThatTune Oct. 19 at 2:35 PM

$RANI $ASMB $QNRX $QURE $IMRX But let's take it a step farther... RANI pre-funded warrants 82 million @ $.48 and exercisable at $.0001 ASMB pre funded warrants Class A + B prefunded warrants at $19.60 below the $21.60 offer price QNRX pre funded warrants This is a nightmare. Series H, I, J, K prefunded warrants for $88 million QURE pre funded warrants 526K @$47.50 and exercisable at $.0001 IMRX pre funded warrants on 8/21 as part of $25 mil PP (secret investor) at $3.95, with option in at $5.50. Stock walks 4.70 to new highs $10+. Then another round on 9/25 with Sanofi $25 mil PP at $9.23 on the heels of "extroardinary" results per the company. For this one, stock more than doubles on a $25 mil private placement to unknown investor. Then a month later they announce another $25 mil private placement from Sanofi and stock drops 40%. Who really knows anything at this point!

0 · Reply

CantNameThatTune Oct. 19 at 11:44 AM

Let's look at the biotech landscape: $RANI Licensing deal Fri w/Chugai ($CHGCY). $60 mil PIPE w/pre-funded warrants. Up 250%. No trial results $ASMB (Hep B+D) 8/25 announces 94% reduction in Hep at 350 mil dose. Announces $175 mil offer at $19.60 with Gilead separate $45 mil at $19.60. Never went red. New 52 highs Fri @ $30.20 $QNRX (Netherton -extremely rare) No trial news. Announces PP on 10/10 in $7's. Stock runs to $41. Now $16's. Up more than 100% $QURE (Huntingtons - extremely rare) on 9/24 announces some trial progression for AMT-130. Stock runs $13's to $50 . Immed announce $200 mil offering. Upsized to $350 mil. Stock hits new 52's last wk $64. $IMRX (Pancreatic cancer) On 9/25 announces world's best survival rate at 6 mos of 94%. Further announcing survival rate of 86% at 9 mos vs. only FDA approved 42% in the market. Announces $175 mil offering with PP from Sanofi $25 mil. Identical to ASMB. Offering & placement @ $9.23 (no discount). Stock now $5.58

1 · Reply

Poldi2021 Oct. 17 at 4:17 PM

$ASMB $BCAB that is funny. I did exactly the other way round. ASMB has too much potential…good 1b results and the Next rocket leaves

1 · Reply

onemillion2012 Oct. 17 at 3:17 PM

$ASMB decreased my holdings. Bought more of $BCAB

1 · Reply

Dachshundtrader Oct. 15 at 4:40 PM

$ASMB – today’s S-3 doesn’t signal selling. It simply registers GILD’s existing holdings so they could be sold later if needed. No new shares, no dilution — and no indication $GILD plans to reduce its stake.

0 · Reply

Poldi2021 Oct. 15 at 3:41 PM

$ASMB I try to figure out what that means/ the purpose is?!

0 · Reply

onemillion2012 Oct. 15 at 3:37 PM

$ASMB nobody talking about the S3 Filling last night. That Gilead is selling it's entire post over 29 percent of the outstanding float. For a maximum price at $24,84 Any thoughts

0 · Reply

Assembly Biosciences Announces Upcoming Investor Conference Participation

Oct 10, 2025, 8:00 AM EDT - 15 days ago

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Sep 29, 2025, 7:11 AM EDT - 26 days ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ATRA CORT

Aug 8, 2025, 4:54 PM EDT - 2 months ago

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Aug 8, 2025, 8:05 AM EDT - 2 months ago

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Aug 8, 2025, 8:00 AM EDT - 2 months ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Jul 26, 2025, 3:00 AM EDT - 3 months ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Jun 30, 2025, 8:00 AM EDT - 4 months ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 25, 2025, 8:00 AM EDT - 4 months ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

May 27, 2025, 4:05 PM EDT - 5 months ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 6 months ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 7, 2025, 8:00 AM EDT - 6 months ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Apr 9, 2025, 2:00 AM EDT - 7 months ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Mar 20, 2025, 4:05 PM EDT - 7 months ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Feb 26, 2025, 8:00 AM EST - 8 months ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 20, 2025, 8:00 AM EST - 8 months ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Dec 26, 2024, 8:00 AM EST - 10 months ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

May 22, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 8, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Feb 8, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Jan 4, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Nov 10, 2023, 4:05 PM EST - 2 years ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 8:00 AM EST - 2 years ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

May 23, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Jan 17, 2023, 7:00 AM EST - 3 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Oct 24, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 20, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Jun 8, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

May 12, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Mar 10, 2022, 4:05 PM EST - 3 years ago

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Feb 9, 2022, 8:00 AM EST - 4 years ago

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

havivi77 Oct. 24 at 8:31 PM

$ASMB accumulation is still on going… explosion has not happened yet…

0 · Reply

Dachshundtrader Oct. 24 at 5:08 PM

$ASMB up ~8% on almost no volume today. Not hype, not noise — just what happens when a tiny float meets a bit of quiet accumulation. Sometimes the calmest days say the most. $GILD

0 · Reply

Jkwran69 Oct. 21 at 7:49 PM

$ASMB did something negative happen at their investment conference today?

1 · Reply

CantNameThatTune Oct. 19 at 2:35 PM

0 · Reply

CantNameThatTune Oct. 19 at 11:44 AM

1 · Reply

Poldi2021 Oct. 17 at 4:17 PM

$ASMB $BCAB that is funny. I did exactly the other way round. ASMB has too much potential…good 1b results and the Next rocket leaves

1 · Reply

onemillion2012 Oct. 17 at 3:17 PM

$ASMB decreased my holdings. Bought more of $BCAB

1 · Reply

Dachshundtrader Oct. 15 at 4:40 PM

0 · Reply

Poldi2021 Oct. 15 at 3:41 PM

$ASMB I try to figure out what that means/ the purpose is?!

0 · Reply

onemillion2012 Oct. 15 at 3:37 PM

$ASMB nobody talking about the S3 Filling last night. That Gilead is selling it's entire post over 29 percent of the outstanding float. For a maximum price at $24,84 Any thoughts

0 · Reply

havivi77 Oct. 14 at 7:35 PM

$ASMB +$50

0 · Reply

HighReturnStocks Oct. 14 at 5:47 PM

$ASMB another banger, still holding all. You all like all these plays like $WKEY. Im also eyeing $CAMP and $CLPS for big gains.

0 · Reply

Dachshundtrader Oct. 14 at 5:23 PM

$ASMB heating up again 🔥 At this pace, $GILD better hurry if they still want the “discount version” 😏 Every green candle makes that buyout a little more expensive 💸

0 · Reply

HighReturnStocks Oct. 14 at 2:40 PM

$CAMP Loved the dip today, grabbed another chunk to my swing $DRMA still holding $ASMB swinging this till we see $30+

0 · Reply

Spiderman77 Oct. 14 at 1:39 PM

$ASMB Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor conferences. H.C. Wainwright Liver Disease Virtual Conference Anuj Gaggar, MD, PhD, chief medical officer, will present in a pre-recorded fireside chat that will be available on demand during the H.C. Wainwright Liver Disease Virtual Conference starting at 7 a.m. Eastern Time on October 21, 2025. Guggenheim 2nd Annual Healthcare Innovation Conference Jason Okazaki, chief executive officer and president, and Dr. Gaggar will present in a fireside chat during the Guggenheim 2nd Annual Healthcare Innovation Conference at 11 a.m. Eastern Time on November 12, 2025.

0 · Reply

onemillion2012 Oct. 14 at 11:48 AM

$ASMB Onemillion2012 updates rating for Assembly Biosciences ( $ASMB ) to strong Buy, target set at $84 → $96

0 · Reply

SearchFor911 Oct. 14 at 11:18 AM

$ASMB $GILD more data incoming in fall 2025. more value incoming 🚀.

0 · Reply

JarvisFlow Oct. 14 at 11:17 AM

HC Wainwright & Co. has adjusted their stance on Assembly Biosciences ( $ASMB ), setting the rating to Buy with a target price of 50.

0 · Reply

DangerDolan Oct. 13 at 7:24 PM

$ASMB

0 · Reply

GimliSonofGloin Oct. 10 at 12:06 PM

$ASMB https://www.stocktitan.net/news/ASMB/assembly-biosciences-presents-interim-phase-1b-data-for-hsv-helicase-7b2ukzyx72tp.html

0 · Reply

Timefortendies77 Oct. 9 at 8:08 PM

$ASMB 1 month data soon?

0 · Reply

Zonata Oct. 8 at 9:33 PM

$ASMB this is primed to break into the 30... imo we'll test 35-38 before EOY. GL to all, and let's hope for a big buyout.

2 · Reply

Market Cap	210.95M
Revenue (ttm)	28.52M
Net Income (ttm)	-40.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.88%
Debt to Equity Ratio	0.00

Volume	74,600
Avg Vol	156,336
Day's Range	N/A - N/A
Shares Out	7.67M
Stochastic %K	57%
Beta	0.60
Analysts	Strong Sell
Price Target	$38.20